Inhibitors of thrombosis
Patent 5492895 Issued on February 20, 1996. Estimated Expiration Date: 
February 14, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
February 14, 2014. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.Patent ReferencesAsp-Pro-Arg -keto-amide enzyme inhibitors Patent #: 5371072 InventorsApplicationNo. 195995 filed on 02/14/1994US Classes:514/18, 3 or 4 peptide repeating units in known peptide chain514/19, 2 peptide repeating units in known peptide chain530/331, Tripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc.530/345, Chemical aftertreatment, e.g., acylation, methylation, etc.548/535, The five-membered hetero ring is further unsubstituted or alkyl substituted only (e.g., proline, etc.)562/571, Polycarboxylic562/573Glutamic acid per se or salt thereofExaminersPrimary: Warden, JillAssistant: Lukton, David Attorney, Agent or FirmInternational ClassA61K 038/06AbstractThis invention relates to peptide aldehyde analogs that inhibit the thrombin or Factor Xa. The compounds are thought useful for preventing or treating conditions in mammal characterized by abnormal thrombosis.Other References
Field of Search3 or 4 peptide repeating units in known peptide chain2 peptide repeating units in known peptide chain 4 to 5 amino acid residues in defined sequence Tripeptides, e.g., tripeptide thyroliberin (TRH), melanostatin (MIF), etc. Chemical aftertreatment, e.g., acylation, methylation, etc. The five-membered hetero ring is further unsubstituted or alkyl substituted only (e.g., proline, etc.) Polycarboxylic Glutamic acid per se or salt thereof |
| ||||||||||||||
